Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
Want to see STOK full AI Analyst Report?
Top Page
Stoke Therapeutics
(NASDAQ:STOK)
Select Model
Select Model
Rating:58Neutral
Price Target:
$34.00
▼(-8.77% Downside)
Action:ReiteratedDate:04/08/26
The score is driven primarily by improving financial momentum (positive 2025 operating/free cash flow and a strong, debt-free balance sheet), partially offset by continued net losses and weak earnings-based valuation (negative P/E). Technical signals are mixed to slightly soft, while recent corporate updates add incremental support via clinical timeline acceleration and governance/operational strengthening.
Positive Factors
Balance Sheet Strength
Essentially zero debt and a sizable equity base ($352.5M of equity on $418.4M assets in 2025) materially reduce financial risk. This structural strength gives management flexibility to fund clinical programs, absorb trial delays, and pursue R&D without immediate reliance on dilutive financing.
Negative Factors
Persistent Net Losses
Despite a marked improvement in 2025, the company has a history of multi-year net losses and negative returns. Ongoing unprofitable operations mean long-term viability depends on drug approvals or consistent non-dilutive revenues; profitability is not yet structurally established.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Essentially zero debt and a sizable equity base ($352.5M of equity on $418.4M assets in 2025) materially reduce financial risk. This structural strength gives management flexibility to fund clinical programs, absorb trial delays, and pursue R&D without immediate reliance on dilutive financing.
Read all positive factors
Stoke Therapeutics (STOK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.06B
Dividend YieldN/A
Average Volume (3M)805.33K
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue Growth404.50%
EPS Growth94.17%
CountryUS
Employees128
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding62,271,084
10 Day Avg. Volume605,386
30 Day Avg. Volume805,331
Financial Highlights & Ratios
PEG Ratio2.94
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue10.51
Enterprise Value/Gross Profit10.62
Enterprise Value/Ebitda-136.89
Forecast
1Y Price Target
$46.71Price Target Upside25.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$26.96M
Stoke Therapeutics Business Overview & Revenue Model
Company Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targe...
How the Company Makes Money
Stoke Therapeutics does not currently generate meaningful recurring revenue from product sales and has historically operated at a loss while funding research and development. Its revenue, when present, primarily comes from collaboration and licens...
Stoke Therapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 184.42M | 36.55M | 8.78M | 12.40M | 0.00 |
| Gross Profit | 184.42M | 36.55M | 8.78M | 12.40M | 0.00 |
| EBITDA | -18.82M | -99.19M | -112.30M | -102.81M | -85.09M |
| Net Income | -6.88M | -88.98M | -104.70M | -101.07M | -85.81M |
Balance Sheet | |||||
| Total Assets | 418.43M | 271.56M | 228.34M | 256.07M | 238.87M |
| Cash, Cash Equivalents and Short-Term Investments | 284.67M | 216.90M | 201.39M | 229.59M | 219.81M |
| Total Debt | 0.00 | 2.32M | 2.06M | 2.36M | 1.51M |
| Total Liabilities | 65.98M | 42.53M | 68.78M | 71.22M | 21.09M |
| Stockholders Equity | 352.46M | 229.02M | 159.56M | 184.85M | 217.78M |
Cash Flow | |||||
| Free Cash Flow | 44.91M | -87.05M | -82.68M | -35.83M | -68.11M |
| Operating Cash Flow | 45.59M | -86.85M | -81.07M | -31.87M | -66.91M |
| Investing Cash Flow | -186.81M | -107.47M | 105.95M | -45.88M | -76.43M |
| Financing Cash Flow | 97.39M | 131.09M | 53.01M | 46.41M | 1.28M |
Stoke Therapeutics Technical Analysis
Positive
37.27
Price Trends
34.04
Positive
32.71
Positive
27.12
Positive
Market Momentum
0.62
Negative
63.08
Neutral
82.98
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STOK, the sentiment is Positive. The current price of 37.27 is above the 20-day moving average (MA) of 33.92, above the 50-day MA of 34.04, and above the 200-day MA of 27.12, indicating a bullish trend. The MACD of 0.62 indicates Negative momentum. The RSI at 63.08 is Neutral, neither overbought nor oversold. The STOCH value of 82.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STOK.
Stoke Therapeutics Risk Analysis
Stoke Therapeutics disclosed 67 risk factors in its most recent earnings report. Stoke Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stoke Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.62B | -12.79 | -28.85% | ― | ― | -33.82% | |
58 Neutral | $2.06B | -273.00 | -2.05% | ― | 404.50% | 94.17% | |
56 Neutral | $1.08B | 2,273.17 | -5.33% | ― | 43.72% | 99.47% | |
55 Neutral | $1.76B | -20.11 | -22.87% | ― | ― | -21.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.69B | -11.85 | -206.62% | ― | 397.28% | 27.68% |
* Healthcare Sector Average
STOK
Stoke Therapeutics
33.08
23.38
241.03%
SNDX
Syndax Pharmaceuticals
19.11
5.54
40.83%
XERS
Xeris Pharmaceuticals
6.28
1.64
35.34%
RAPP
Rapport Therapeutics, Inc.
33.89
22.91
208.65%
SION
Sionna Therapeutics, Inc.
39.15
26.36
206.10%
Stoke Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight
Positive
Apr 7, 2026
On April 3, 2026, Stoke Therapeutics’ board expanded to ten members and appointed veteran drug development and regulatory executive Clare Kahn, Ph.D., as an independent Class I director, with her term running until the 2026 annual shareholde...
Executive/Board ChangesFinancial Disclosures
Stoke Therapeutics Awards Discretionary Bonus to CEO Smith
Positive
Mar 3, 2026
On February 13, 2026, Stoke Therapeutics’ board approved a discretionary bonus of $697,125 for Chief Executive Officer Ian F. Smith, matching his full target annual bonus for 2025 despite his non-participation in the regular annual bonus pro...
Business Operations and Strategy
Stoke Therapeutics Expands with New Long-Term Waltham Headquarters
Positive
Jan 26, 2026
On January 21, 2026, Stoke Therapeutics, Inc. signed a long-term lease for a new corporate headquarters and laboratory at 245 Fifth Avenue in Waltham, Massachusetts, expanding its facilities to approximately 98,500 square feet. The lease runs thro...
Business Operations and StrategyProduct-Related Announcements
Stoke Therapeutics Accelerates Phase 3 Dravet Study Timeline
Positive
Jan 12, 2026
On January 11, 2026, Stoke Therapeutics announced updated, accelerated timelines for its Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, now expecting to complete enrollment of 150 patients in the second quarter of 2026 and to deliver a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.